Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PBM Mergers: Vertical Integration Is Cool – But Don’t Overlook Horizontal Consolidation In Part D

Executive Summary

It is hard not to get caught up in the excitement of reinventing health care deliver amid the wave of retail, PBM and insurer merger agreements and rumors. But there is an immediate impact that might be overlooked: the Medicare Part D market is going to be much more consolidated.

You may also be interested in...



WellCare To Triple Medicare Part D Membership With Purchase Of Aetna Plans

Divestiture prevents CVS from gaining even more dominance in the stand-alone Medicare Part D sector with its acquisition of Aetna, assuming the transaction is cleared by the government.

Deal Watch: Cigna Acquisition Of Express Scripts OKed By US Justice Dept.

It remains unclear what impact the consolidation within the drug-distribution sector may have on pricing. Pfizer partners with France’s Cytoo for its new gene therapy approach to DMD, while Gilead teams with Precision BioSciences for its goal to cure HBV.

Mysterious Amazon/Berkshire/JPMorgan Partnership Could Disrupt Health Care, Pharma

The collective bargaining power of the three large employers, potentially assisted by Amazon's low-cost distribution channels, could be a formidable force in negotiating lower cost and better quality health care services, including pharmaceutical products.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122870

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel